Metabolomic Patterns in Adolescents With Mild to Moderate CKD

Brooks, Ellen R.; Lin, David C.; Langman, Craig B.; Thompson, J. Will; John-Williams, Lisa St.; Furth, Susan L.; Warady, Bradley A.; Haymond, Shannon

doi:10.1016/j.ekir.2019.01.009

Cited by 5 publications

(7 citation statements)

References 16 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Activation of Trp metabolism by inflammation leads to changes in levels of metabolites within the Kyn pathway and then the secretion of anti-inflammatory cytokines [[17]]. In a targeted metabolomic analysis of plasma samples collected in the Chronic Kidney Disease in Children (CKiD) study cohort, Trp, Kyn, and the ratio of Kyn to Trp were significantly associated with the stage of CKD [[19]]. Kyn and Kyn/Trp were also found to be associated with the onset and progression of CKD in large population-based cross-sectional studies, suggesting the potential to be used as prognostic markers [[20], [21]].…”

Section: Metabolites Of the Amino Acid Super Pathwaymentioning

confidence: 99%

“…Based on liquid chromatography-quadrupole-time-of-flight mass spectrometry (LC-QTOF-MS), plasma concentrations of glycine, citrulline, ADMA, and SDMA were increased, regardless of creatinine level, in 32 children with CKD (aged 6–18 years) compared to healthy controls (aged 6–19 years) [[24]]. The ratio of SDMA to ADMA (SDMA/ADMA) was found to increase with greater CKD severity [[19]]. The accuracy of classifying early CKD samples and healthy controls was improved from 71% based on serum creatinine only to 89% based on SDMA, citrulline, and S-adenosylmethionine in addition to serum creatinine [[25]].…”

Section: Metabolites Of the Amino Acid Super Pathwaymentioning

confidence: 99%

See 1 more Smart Citation

Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease

Sandokji¹,

Xu²,

Furth³

et al. 2023

Nephron

View full text Add to dashboard Cite

Background: Due to the complexity of chronic kidney disease (CKD) pathophysiology, biomarkers representing different mechanistic pathways have been targeted for the study and development of novel biomarkers. The discovery of clinically useful CKD biomarkers would allow for the identification of those children at the highest risk of kidney function decline for timely interventions and enrollment in clinical trials. Summary: Glomerular filtration rate and proteinuria are traditional biomarkers to classify and prognosticate CKD progression in clinical practice but have several limitations. Over the recent decades, novel biomarkers have been identified from blood or urine with metabolomic screening studies, proteomic screening studies, and an improved knowledge of CKD pathophysiology. This review highlights promising biomarkers associated with the progression of CKD that could potentially serve as future prognostic markers in children with CKD. Key Messages: Further studies are needed in children with CKD to validate putative biomarkers, particularly candidate proteins and metabolites, for improving clinical management.

show abstract

Section: Metabolites Of the Amino Acid Super Pathwaymentioning

confidence: 99%

Section: Metabolites Of the Amino Acid Super Pathwaymentioning

confidence: 99%

Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease

Sandokji¹,

Xu²,

Furth³

et al. 2023

Nephron

View full text Add to dashboard Cite

show abstract

“…Given that, the discovery of new biomarkers for early CKD diagnosis might dramatically improve the overall management of the disease. In this scenario, metabolomics might provide novel insights in this field [ 11 , 70 , 72 , 74 ] ( Table 3 ).…”

Section: Metabolomics In Chronic Kidney Disease (Ckd)mentioning

confidence: 99%

“…Targeted metabolomics was also used by Brooks et al [ 74 ] to explore changes in metabolites when passing from a stage 2 to stage 3b of CKD. They identified five metabolites (phosphatidylcoline, tryptophan (Trp), kynurenine (Kyn), creatinine (Cr), and acylcarnitine) and ratios (tyrosine/creatinine (Tyr/Cr), ornithine/citrulline (Orn/Cit), Kyn/Trp, proline/Cit (Pro/Cit), phenylalanine/Trp (Phe/Trp), and SDMA/ADMA) which were significantly different between the cohorts, likely due to the change in kidney function between the two stages [ 74 ].…”

Section: Metabolomics In Chronic Kidney Disease (Ckd)mentioning

confidence: 99%

New Insights from Metabolomics in Pediatric Renal Diseases

Riccio¹,

Valentino²,

Passaro³

et al. 2022

Children

View full text Add to dashboard Cite

Renal diseases in childhood form a spectrum of different conditions with potential long-term consequences. Given that, a great effort has been made by researchers to identify candidate biomarkers that are able to influence diagnosis and prognosis, in particular by using omics techniques (e.g., metabolomics, lipidomics, genomics, and transcriptomics). Over the past decades, metabolomics has added a promising number of ‘new’ biomarkers to the ‘old’ group through better physiopathological knowledge, paving the way for insightful perspectives on the management of different renal diseases. We aimed to summarize the most recent omics evidence in the main renal pediatric diseases (including acute renal injury, kidney transplantation, chronic kidney disease, renal dysplasia, vesicoureteral reflux, and lithiasis) in this narrative review.

show abstract

“…As CKD progression is concomitant with altered metabolism, a number of metabolites are being studied as potential biomarkers [ 64 , 116 ]. Untargeted metabolomics for biomarker discovery has been applied in pediatric CKD [ 117 , 118 , 119 , 120 , 121 ]. In early stage of CKD, one metabolic study revealed that sphingosine-1-phosphate, cis-4-decenoylcarnitine, n-butyrylcarnitine, and aminoadipic acid were increased in children with CKD, while bilirubin was decreased [ 117 ].…”

Section: Cardiovascular Risks and Biomarkers In Pediatric Ckdmentioning

confidence: 99%

Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease

Tain

Hsu²

2022

Children

View full text Add to dashboard Cite

Hypertension is the most common complication of chronic kidney disease (CKD) in children, having a strong association with subsequential cardiovascular disease (CVD). In pediatric CKD, a considerable percentage of children with hypertension are undiagnosed or undertreated. Prior research has evaluated structural and functional markers of subclinical CVD and biomarkers in adults with CKD, while ideal biomarkers in pediatrics are still insufficiently studied. The ultimate goal of this review is to summarize what is currently known about state of hypertension, cardiovascular risk factors, and potential CVD markers/biomarkers in children with pre-dialysis CKD. We discuss omics-related biomarkers and the pathophysiologic processes of endothelial dysfunction, kidney injury, oxidative stress and inflammation that are classified by specific biomarkers. Moreover, we illustrate the existing challenges and highlight the paucity of pediatric CKD research to evaluate these CVD biomarkers for future clinical pediatric practice. Thus, achieving clinical utility of CVD biomarkers for use in pediatric CKD remains a significant challenge requiring additional efforts.

show abstract

Metabolomic Patterns in Adolescents With Mild to Moderate CKD

Cited by 5 publications

References 16 publications

Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease

Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease

New Insights from Metabolomics in Pediatric Renal Diseases

Cardiovascular Risks of Hypertension: Lessons from Children with Chronic Kidney Disease

Contact Info

Product

Resources

About